Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
$2.97
+1.7%
$2.34
$1.26
$3.12
$82.79M0.24153,736 shs278,471 shs
NextCure, Inc. stock logo
NXTC
NextCure
$4.99
-2.7%
$5.67
$2.69
$21.48
$13.35M1.0611,618 shs29,253 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$3.89
+4.6%
$2.99
$1.14
$7.47
$120.49M1.95513,462 shs320,616 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.88
+1.3%
$0.57
$0.36
$4.06
$142.68M32.81 million shs4.27 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
0.00%+12.08%+24.27%+78.92%+36.24%
NextCure, Inc. stock logo
NXTC
NextCure
0.00%+5.27%-8.12%+15.13%-76.37%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
0.00%-2.26%+81.78%+171.08%-38.35%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
0.00%+28.38%+51.62%+94.91%-75.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3.1196 of 5 stars
3.55.00.00.00.03.30.6
NextCure, Inc. stock logo
NXTC
NextCure
4.2354 of 5 stars
3.43.00.04.31.51.71.3
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.7732 of 5 stars
3.54.00.00.01.10.00.0
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.2719 of 5 stars
3.53.00.00.00.64.21.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3.00
Buy$7.00135.69% Upside
NextCure, Inc. stock logo
NXTC
NextCure
2.75
Moderate Buy$33.00561.32% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60326.74% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.00
Buy$6.25612.58% Upside

Current Analyst Ratings Breakdown

Latest NXTC, SKYE, TNYA, and IMMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
NextCure, Inc. stock logo
NXTC
NextCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$36.00 ➝ $15.00
7/8/2025
NextCure, Inc. stock logo
NXTC
NextCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/1/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/24/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
6/4/2025
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/9/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/25/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/A$0.48 per shareN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$28.06 per shareN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$2.25 per shareN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$1.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)
NextCure, Inc. stock logo
NXTC
NextCure
-$55.65M-$21.13N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$111.13M-$1.16N/AN/AN/AN/A-92.20%-74.53%8/14/2025 (Estimated)

Latest NXTC, SKYE, TNYA, and IMMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.17N/AN/AN/AN/AN/A
8/11/2025Q1 2025
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$0.21N/AN/AN/AN/AN/A
8/7/2025Q2 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.39N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
5/7/2025Q1 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.18-$0.24-$0.06-$0.24N/AN/A
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$4.80-$4.68+$0.12-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/A
1.80
1.80
NextCure, Inc. stock logo
NXTC
NextCure
N/A
10.26
10.26
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
11.85
11.85
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
6.68
6.68

Institutional Ownership

CompanyInstitutional Ownership
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
11.26%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%

Insider Ownership

CompanyInsider Ownership
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
55.40%
NextCure, Inc. stock logo
NXTC
NextCure
17.90%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
48.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
927.88 million12.43 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
902.68 million2.20 millionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.58 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110162.67 million83.53 millionOptionable

Recent News About These Companies

Tenaya announces interim data from ongoing RIDGE study

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immix Biopharma stock logo

Immix Biopharma NASDAQ:IMMX

$2.97 +0.05 (+1.71%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.91 -0.06 (-2.02%)
As of 07/18/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

NextCure stock logo

NextCure NASDAQ:NXTC

$4.99 -0.14 (-2.73%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$5.05 +0.06 (+1.20%)
As of 07/18/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$3.89 +0.17 (+4.57%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.92 +0.03 (+0.77%)
As of 07/18/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$0.88 +0.01 (+1.27%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.86 -0.02 (-2.41%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.